Oral vinorelbine dose arms | ||||
---|---|---|---|---|
30 mg | 40 mg | 50 mg | ||
Patients | N | 27 | 24 | 22 |
Age | median | 67 | 66 | 67 |
range | 43-74 | 48-75 | 44-75 | |
Gender | Male | 18 (66.6%) | 17 (70.8%) | 15 (68.2%) |
Female | 9 (33.4%) | 7 (29.2%) | 7 (31.8) | |
Cancer type | Breast | 7 (26.0%) | 6 (25.0%) | 7 (31.8%) |
Prostate | 8 (29.6%) | 7 (29.2%) | 7 (31.8%) | |
NSCLC | 12 (44.4%) | 11 (45.8%) | 8 (36.4%) | |
PS | 0 | 8 (29.6%) | 10 (41.6%) | 8 (36.4%) |
1 | 15 (55.6%) | 11 (45.8%) | 12 (54.6%) | |
2 | 4 (14.8%) | 3 (12.6%) | 2 (9.0%) | |
Prior chemotherapy | 0 | 5 (18.6%) | 4 (16.6%) | 5 (22.8%) |
1 | 13 (48.2%) | 12 (50.0%) | 11 (50.0%) | |
2 | 9 (33.4%) | 8 (33.4%) | 6 (27.2%) | |
Prior radiotherapy | 14 (51.8%) | 8 (33.4%) | 11 (50.0%) | |
Prior hormonotherapy | 12 (44.4%) | 11 (44.8%) | 13 (59.0%) | |
Organs with metastases | lung | 15 (55.6%) | 14 (58.4%) | 10 (45.4%) |
liver | 8 (29.6%) | 4 (16.6%) | 3 (13.6%) | |
bone | 18 (66.6%) | 15 (62.6%) | 9 (41%) |